Your browser doesn't support javascript.
loading
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.
Hoeper, Marius M; Pausch, Christine; Grünig, Ekkehard; Klose, Hans; Staehler, Gerd; Huscher, Doerte; Pittrow, David; Olsson, Karen M; Vizza, Carmine Dario; Gall, Henning; Benjamin, Nicola; Distler, Oliver; Opitz, Christian; Gibbs, J Simon R; Delcroix, Marion; Ghofrani, H Ardeschir; Rosenkranz, Stephan; Ewert, Ralf; Kaemmerer, Harald; Lange, Tobias J; Kabitz, Hans-Joachim; Skowasch, Dirk; Skride, Andris; Jureviciene, Elena; Paleviciute, Egle; Miliauskas, Skaidrius; Claussen, Martin; Behr, Juergen; Milger, Katrin; Halank, Michael; Wilkens, Heinrike; Wirtz, Hubert; Pfeuffer-Jovic, Elena; Harbaum, Lars; Scholtz, Werner; Dumitrescu, Daniel; Bruch, Leonhard; Coghlan, Gerry; Neurohr, Claus; Tsangaris, Iraklis; Gorenflo, Matthias; Scelsi, Laura; Vonk-Noordegraaf, Anton; Ulrich, Silvia; Held, Matthias.
Affiliation
  • Hoeper MM; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; German Center of Lung Research (DZL), Hannover, Germany. Electronic address: hoeper.marius@mh-hannover.de.
  • Pausch C; Epidemiological Center, GWT-TUD GmbH, Dresden, Germany.
  • Grünig E; Centre for Pulmonary Hypertension, Thoraxclinic Heidelberg GmbH at Heidelberg University Hospital, Heidelberg, Germany.
  • Klose H; Department of Respiratory Medicine, Eppendorf University Hospital, Hamburg, Germany.
  • Staehler G; Lungenklinik, Löwenstein, Germany.
  • Huscher D; Institute of Biometry and Clinical Epidemiology, Charité Universitätsmedizin, Berlin, Germany.
  • Pittrow D; Epidemiological Center, GWT-TUD GmbH, Dresden, Germany; Medical Faculty, Institute for Clinical Pharmacology, Technical University Dresden, Dresden, Germany.
  • Olsson KM; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; German Center of Lung Research (DZL), Hannover, Germany.
  • Vizza CD; Department of Cardiovascular and Respiratory Diseases, Sapienza, University of Rome, Rome, Italy.
  • Gall H; Department of Internal Medicine, Justus-Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; German Center of Lung Research (DZL), Hannover, Germany.
  • Benjamin N; Centre for Pulmonary Hypertension, Thoraxclinic Heidelberg GmbH at Heidelberg University Hospital, Heidelberg, Germany.
  • Distler O; Department of Rheumatology, University Hospital, Zurich, Switzerland.
  • Opitz C; Department of Cardiology, DRK Kliniken Berlin Westend, Berlin, Germany.
  • Gibbs JSR; Department of Cardiology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Delcroix M; Department of Pneumology, University Hospital Leuven, Leuven, Belgium.
  • Ghofrani HA; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; Department of Internal Medicine, Justus-Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; Department of Medicine, Imperial College, London, London, United Kingdom.
  • Rosenkranz S; Clinic III for Internal Medicine (Cardiology); Center for Molecular Medicine; Cologne Cardiovascular Research Center (CCRC), University of Cologne, Cologne, Germany.
  • Ewert R; Department of Respiratory Medicine, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany.
  • Kaemmerer H; Deutsches Herzzentrum München, Klinik für angeborene Herzfehler und Kinderkardiologie, TU München, Munich, Germany.
  • Lange TJ; Department of Internal Medicine II, University Medical Center Regensburg, Regensburg, Germany.
  • Kabitz HJ; Gemeinnützige Krankenhausbetriebsgesellschaft Konstanz mbH, Medizinische Klinik II, Konstanz, Germany.
  • Skowasch D; Innere Medizin - Kardiologie/Pneumologie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Bonn, Germany.
  • Skride A; VSIA Pauls Stradins Clinical University Hospital, Riga Stradins University, Riga, Latvia.
  • Jureviciene E; Faculty of Medicine of Vilnius University, Referral Centre of Pulmonary Hypertension, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Paleviciute E; Faculty of Medicine of Vilnius University, Referral Centre of Pulmonary Hypertension, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Miliauskas S; Department of Pulmonology, Pulmonary Hypertension Center, Hospital of Lithuanian University of Health Sciences, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Claussen M; Pneumologie, Fachabteilung, LungenClinic Grosshansdorf, Grosshansdorf, Germany.
  • Behr J; Comprehensive Pneumology Center, Lungenforschungsambulanz, Helmholtz Zentrum, Munich, Germany; Department of Internal Medicine V, Ludwig Maximilians University of Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany; Department
  • Milger K; Department of Internal Medicine V, Ludwig Maximilians University of Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.
  • Halank M; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden, Germany.
  • Wilkens H; Klinik für Innere Medizin, Pneumologie, Universitätsklinikum Universitätskliniken des Saarlandes, Homburg, Germany.
  • Wirtz H; Abteilung für Pneumologie, Medizinische Klinik und Poliklinik I, Universitätsklinikum Leipzig, Leipzig, Germany.
  • Pfeuffer-Jovic E; Department of Internal Medicine, Respiratory Medicine and Ventilatory Support, Medical Mission Hospital, Central Clinic Würzburg, Würzburg, Germany.
  • Harbaum L; Department of Respiratory Medicine, Eppendorf University Hospital, Hamburg, Germany.
  • Scholtz W; Clinic for General and Interventional Cardiology and Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
  • Dumitrescu D; Clinic for General and Interventional Cardiology and Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
  • Bruch L; Klinik für Innere Medizin/Kardiologie, Unfallkrankenhaus Berlin, Berlin, Germany.
  • Coghlan G; Cardiology, Royal Free Hospital, London, United Kingdom.
  • Neurohr C; Abteilung für Pneumologie und Beatmungsmedizin, Klinik Schillerhöhe, Gerlingen, Germany.
  • Tsangaris I; 2nd Critical Care Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Gorenflo M; Klinik für Angeborene Herzfehler und Kinderkardiologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.
  • Scelsi L; Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Vonk-Noordegraaf A; Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Ulrich S; Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.
  • Held M; Clinic for General and Interventional Cardiology and Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
J Heart Lung Transplant ; 39(12): 1435-1444, 2020 12.
Article in En | MEDLINE | ID: mdl-33082079
ABSTRACT
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward's minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters were identified Cluster 1 (n = 106; 12.6%) median age 45 years, 76% females, no comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%) median age 75 years, 98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3 (n = 434; 51.6%) median age 72 years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Wedge Pressure / Registries / Familial Primary Pulmonary Hypertension / Lung Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Heart Lung Transplant Journal subject: CARDIOLOGIA / TRANSPLANTE Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Wedge Pressure / Registries / Familial Primary Pulmonary Hypertension / Lung Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Heart Lung Transplant Journal subject: CARDIOLOGIA / TRANSPLANTE Year: 2020 Document type: Article